| Literature DB >> 36118578 |
Li Xiaoshuai1, Wang Qiushi1, Wang Rui2.
Abstract
In the past 10 years, gene-editing and organoid culture have completely changed the process of biology. Congenital nervous system malformations are difficult to study due to their polygenic pathogenicity, the complexity of cellular and neural regions of the brain, and the dysregulation of specific neurodevelopmental processes in humans. Therefore, the combined application of CRISPR-Cas9 in organoid models may provide a technical platform for studying organ development and congenital diseases. Here, we first summarize the occurrence of congenital neurological malformations and discuss the different modeling methods of congenital nervous system malformations. After that, it focuses on using organoid to model congenital nervous system malformations. Then we summarized the application of CRISPR-Cas9 in the organoid platform to study the pathogenesis and treatment strategies of congenital nervous system malformations and finally looked forward to the future.Entities:
Keywords: 3D; CRISPR-Cas9; central nervous system; congenital nervous system malformation; organoid
Year: 2022 PMID: 36118578 PMCID: PMC9478582 DOI: 10.3389/fbioe.2022.932936
Source DB: PubMed Journal: Front Bioeng Biotechnol ISSN: 2296-4185
FIGURE 2Application of brain organoid in CNSM. Patient-derived somatic cells reprogrammed into iPSCs can be differentiated into neurons and glial cells. The 2D co-culture models can analyze the interaction of different brain cell types. CRISPR-Cas9 can also be used to edit iPSCs, and observe the related characteristics of brain organoids, so as to determine the related mechanism of disease occurrence. Brain organoid can be used in different CNSM models to analyze the pathology of diseases, evaluate the efficacy of newly developed compounds in drug screening and toxicity research, and make non-invasive prenatal testing clinically.
FIGURE 1Application CRISPR-Cas9 to generate disease model. Models can be generated by either knocking out a healthy gene or rescuing a defective gene in cells. (A) Somatic cells from healthy people are reprogrammed into iPSCs. Specific disease-causing mutations can be introduced to genes in these cells by either knocking in defective genes or introducing INDEL through genome editing. (B) Somatic cells from patients can be isolated and reprogrammed into iPSCs. The mutation in these patient iPSCs can be corrected by the delivery of CRISPR-Cas9 introducing a nomal gene.
Application of brain organoid models and/or CRISPER-Cas9 in CNSM.
| Cell type | Gene | Disease model | Patient-derived (Y/N) | CRISPER-Cas9(Y/N) | References |
|---|---|---|---|---|---|
| iPSC | CDK5RAP2 | Microcephaly | Y | N |
|
| iPSC | TREX1 | Aicardi Goutieres syndrome | Y | N |
|
| iPSC | PTEN | Microcephaly | Y | N |
|
| iPSC | STRADA | Macrocephaly | Y | N |
|
| iPSC | 16p11.2 region | Macrocephaly and microcephaly | Y | N |
|
| ESC | RAD9B | Spina bifida | N | N |
|
| iPSC | RAB39b | Macrocephaly | Y | Y |
|
| iPSC | FMR1 | Macrocephaly | N | Y |
|
| ESC | OCLN | Microcephaly and cortical malformation | N | Y |
|
| iPSC | CPAP-E1235V | Microcephaly | Y | Y |
|
| iPSC | SURF1 | Leigh syndrome | Y | Y |
|
| iPSC | HEXB | Sandhoff disease | Y | Y |
|